Voltage-gated inwardly rectifying potassium channel KCNH2

BE0000090ProteinHumansKCNH2

Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). It is acted on by 84 drugs in DrugBank.

Gene name
KCNH2
UniProtKB entry
Q12809Swiss-Prot
Cellular location
Cell membrane
Residues / weight
1,159 residues · 126,654 Da
Also known as
Eag homolog · Eag-related protein 1 · ERG · ERG-1 · ERG1

Resolves to

Protein
UniProtQ12809UniProt nameKCNH2_HUMAN
Gene
HGNCHGNC:6251NCBI Gene3757GenBank487738GeneCardsKCNH2
Pharmacology
IUPHAR/GtoPdb572KEGGhsa:3757
Structure
PDB1BYWPDB1UJLPDB2L0W
Drugs

What you can answer from here — as of October 08, 2024

84DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
2Clinical trialsTrials of drugs acting on it, by phase and status
Sign in
9GO termsFunction, process and component, as structured annotations
Sign in
3Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
272+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Voltage-gated inwardly rectifying potassium channel KCNH2, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In